pagibaximab

 

Topic mentions per year

Topic mentions per year

2009-2015
012320092015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
INTRODUCTION Advances in modern medicine have given very low birth weight (VLBW) infants a better chance of survival; however… (More)
  • table 3
  • table 4
  • table 1
  • table 5
  • table 6
Is this relevant?
2011
2011
BACKGROUND Pagibaximab, a human chimeric monoclonal antibody developed against lipoteichoic acid, was effective against… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Review
2011
Review
2011
This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates… (More)
Is this relevant?
Review
2011
Review
2011
Sepsis-related morbidity and mortality are major problems in NICU. Preterm neonates display clinical characteristics that make… (More)
Is this relevant?
2009
2009
Staphylococcal sepsis is a major cause of morbidity and mortality in very-low-birth-weight (VLBW) infants. A human chimeric… (More)
Is this relevant?
2009
2009
A chimerized (murine/human) monoclonal antibody (pagibaximab) against lipoteichoic acid (LTA) and protective in animal models for… (More)
Is this relevant?